The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens

BACKGROUND: Lung cancer is the most common cause of cancer-related mortality worldwide despite diagnostic improvements and the development of targeted therapies, notably including epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The phosphoinositide 3-kinase (PI3K)/AKT/mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yi-Ying, Wu, Hung-Chang, Wu, Jia-En, Huang, Kuo-Yen, Yang, Shuenn-Chen, Chen, Si-Xuan, Tsao, Chao-Jung, Hsu, Keng-Fu, Chen, Yuh-Ling, Hong, Tse-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604380/
https://www.ncbi.nlm.nih.gov/pubmed/31262325
http://dx.doi.org/10.1186/s13046-019-1282-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604380/
https://www.ncbi.nlm.nih.gov/pubmed/31262325
http://dx.doi.org/10.1186/s13046-019-1282-0

Ejemplares similares